| scholarly article | Q13442814 |
| P50 | author | Daniel J. Sargent | Q43055483 |
| Charles S. Fuchs | Q88762246 | ||
| P2093 | author name string | Richard M Goldberg | |
| Erin Green | |||
| Philip J Stella | |||
| Roscoe F Morton | |||
| Muhammad Salim | |||
| James A Mailliard | |||
| Paul L Schaefer | |||
| Thierry Delaunoit | |||
| Brian P Findlay | |||
| Sachdev P Thomas | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| Cancer statistics, 2002 | Q28216788 | ||
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel | Q34371152 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program | Q35009894 | ||
| A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients | Q43596239 | ||
| Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer | Q43679342 | ||
| A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients | Q43763447 | ||
| Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer | Q43993881 | ||
| A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin | Q44177901 | ||
| Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study | Q44664927 | ||
| Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project | Q68056139 | ||
| Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study | Q73117412 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irinotecan | Q412197 |
| oxaliplatin | Q422327 | ||
| P304 | page(s) | 2170-2176 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. | |
| P478 | volume | 101 |
| Q25257549 | A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection |
| Q34987417 | A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment |
| Q50041173 | An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma |
| Q36187034 | Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer |
| Q37085987 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. |
| Q24236634 | Chemotherapy for advanced gastric cancer |
| Q24244040 | Chemotherapy for advanced gastric cancer |
| Q35596937 | Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients |
| Q36960766 | Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach |
| Q33759532 | Current status of pharmacological treatment of colorectal cancer |
| Q47126141 | Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients |
| Q49195473 | Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). |
| Q38080794 | Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
| Q35834442 | Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the O |
| Q33383727 | Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 |
| Q37305399 | Gastrointestinal complications of oncologic therapy |
| Q34048515 | Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics |
| Q43131583 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies |
| Q34050521 | NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. |
| Q37875058 | Optimal management of metastatic colorectal cancer: current status |
| Q37780016 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. |
| Q36627254 | Recent developments in colorectal cancer treatment by monoclonal antibodies |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q46987043 | Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis |
| Q37345922 | Systemic and targeted therapy for advanced colon cancer |
| Q90418477 | The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis |
Search more.